ATTBF - Abattis Bioceuticals Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.13327
-0.00173 (-1.28%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.13500
Open0.13300
Bid0.00000 x 0
Ask0.00000 x 0
Day's Range0.13000 - 0.14100
52 Week Range0.07490 - 0.74440
Volume733,688
Avg. Volume1,386,592
Market Cap55.938M
Beta2.51
PE Ratio (TTM)N/A
EPS (TTM)-0.08100
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Emerald Health Therapeutics Completes Acquisition of Licensed Dealer Northern Vine Canada

    Northern Vine is a Licensed Dealer (LD) under the provisions of the Canadian Controlled Drugs and Substances Act. The dealer license allows Emerald to participate in the growing market for cannabis analytical testing, which Emerald expects to grow in conjunction with increasing cannabis production volumes in Canada.

  • GlobeNewswire5 days ago

    Abattis Completes Sale of Northern Vine Interest

    Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT / OTC: ATTBF) is pleased to announce that it has completed the sale (the “Sale”) of its 35% interest in Northern Vine Canada Inc. (“Northern Vine”) to Emerald Health Therapeutics, Inc. (TSXV:EMH / OTCQX:EMHTF) (“Emerald”) in exchange for $2 million in cash and $4 million in common shares of Emerald, 50% of which are free trading and 50% of which may be sold in 30 days. The share purchase agreement governing the Disposition (the “Agreement”) also provides that, upon Northern Vine and/or Emerald earning gross revenues of $10 million from the sale of products or provision of services to customers introduced by Abattis, Emerald will issue Abattis an additional $4 million in common shares of Emerald.

  • GlobeNewswire12 days ago

    Abattis Announces Share Buy Back Program

    Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that it intends to proceed with a normal course issuer bid to purchase up to 20,986,909 of its common shares, representing 5% of its current issued and outstanding shares (the “Bid”). The Company is commencing the Bid because it believes that, from time to time, the market price of its common shares may not fully reflect the underlying value of the Company’s business and future prospects. The Company believes that, at such times, the repurchase of its common shares for cancellation would be in the best interests of its shareholders.

  • GlobeNewswire19 days ago

    Abattis Continues to Build on Recent Investments With Plans for Significant Revenue Growth

    Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to provide an update as the Company moves to a phase of building on recent investments and anticipates significant revenue growth in the fourth quarter of 2018. Through its master services agreement with Northern Vine, the Company continues to have preferential access to a licensed lab, which will enable it to progress its research and development partnerships with the University of British Columbia, exploring nanoemulsified and liposomal platforms for transmucosal delivery of cannabinoid-rich hemp oil, and Faculty Brewing Company, developing hemp-infused, cannabinoid-rich, THC-free craft beer. The Company has also recently deployed capital, through its investment in XLABS Therapeutics (ONT) Inc. (“XLABS”), which is developing a 10,000 square foot laboratory in Belleville, Ontario.  Through XLABS, the Company hopes to leverage the experience it obtained through the build out of Northern Vine on a much larger scale.  In accordance with the terms of the investment, Abattis President and CEO, Rob Abenante has joined the board of directors of XLABS.

  • GlobeNewswire26 days ago

    Abattis Completes Investment in XLABS Therapeutics to Launch New Cannabis Lab in Ontario

    Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that, further to its news release dated June 28, 2018, it has closed its investment in XLABS Therapeutics (ONT) Inc. (“XLABS”). Together, Abattis and XLABS will be launching a new cannabis laboratory in Belleville, Ontario (the “Laboratory”), to service Ontario’s growing cannabis sector. The Laboratory will be housed in a 320,000 square foot building (the “Belleville Facility”), with plans for an initial build-out of 10,000 square feet and future expansion into the remaining 310,000 square feet through organic growth and further joint ventures.

  • GlobeNewswire26 days ago

    Abattis Bioceuticals Expanding Downstream Cannabis Business into Ontario -- CFN Media

    CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Abattis Bioceuticals Corp.'s (ATT.CN) (ATTBF) recent agreement to develop a new laboratory in Ontario, representing a major expansion into Canada’s most populous province. Abattis has been solidifying and growing its vertically integrated cannabis operations in British Columbia for the last few years. With a licensed producer applicant, cannabis-based product development programs, and a mature product distribution network, Abattis is positioned to control and profit from the highest growth sectors of Canada’s cannabis industry.

  • GlobeNewswirelast month

    Abattis Enters Into Definitive Agreement to Sell Northern Vine Interest

    Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce that it has entered into a definitive agreement (the “Agreement”) with Emerald Health Therapeutics, Inc. (“Emerald”) to dispose of (the “Disposition”) its 35% interest in Northern Vine Canada Inc. (“Northern Vine”) in exchange for $2 million in cash and $4 million in freely tradeable common shares of Emerald. The Agreement also provides that, upon Northern Vine and/or Emerald earning gross revenues of $10 million from the sale of products or services to customers introduced by Abattis, Emerald will issue Abattis a further $4 million in common shares of Emerald.

  • GlobeNewswirelast month

    Emerald Health Therapeutics Completes Full Acquisition of Licensed Dealer Northern Vine to Advance Product Innovation

    Emerald Health Therapeutics, Inc. (EMH.V) (EMHTF) (Emerald) has signed a definitive agreement  (“Agreement”) to acquire the remaining shares of Northern Vine Canada Inc. (Northern Vine), owned by Abattis Bioceuticals Corp. (Abattis) (CSE:ATT) (ATTBF), for $2 million in cash and $4 million in shares of Emerald stock. Northern Vine is a Licensed Dealer (LD) under the provisions of the Canadian Controlled Drugs and Substances Act. “Product innovation is a primary pillar of Emerald’s global business strategy.

  • GlobeNewswirelast month

    Abattis Provides Corporate Updates

    Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to provide the following corporate updates. Abattis has completed a non-brokered private placement for gross proceeds of $2.25 million (the “Proceeds”) through the issuance of 13,235,294 common shares of the Company priced at $0.17 per share. The Company anticipates that the Proceeds will be used to organically grow its existing downstream service division and for general working capital purposes.

  • GlobeNewswire2 months ago

    Abattis Enters Into Definitive Agreement to Launch New Cannabis Lab in Ontario

    Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that it has entered into a definitive investment agreement dated June 27, 2018 (the “Agreement”) with XLABS Therapeutics (ONT) Inc. (“XLABS”) to launch a new Cannabis laboratory in Belleville, Ontario (the “Laboratory”). The Laboratory will be designed to service Ontario’s growing cannabis sector, which currently numbers 59 licensed producers (“LPs”). “This is another very significant milestone for Abattis,” stated Rob Abenante, President and CEO of Abattis.

  • CNW Group2 months ago

    Abattis and BLOCKStrain Execute Letter of Intent for Product Integration and Strategic Partnership

    OTC:ATTBF) ("Abattis") and BLOCKSTRAIN TECHNOLOGY CORP. ("BLOCKStrain") (TSXV: DNAX.V) are pleased to announce that they have signed a letter of intent (the "LOI") to integrate BLOCKStrain's proprietary technology into Abattis's  product and services ecosystem. Through their collaboration, the parties hope to enable Abattis clients to instantly arrange for sales, shipping, testing and analysis of Abattis products and give clients comprehensive visibility over such products over their entire lifecycles. Abattis and BLOCKStrain also intend to explore development and integration opportunities to expand on Abattis's current life sciences and biotechnology services offerings.

  • GlobeNewswire3 months ago

    Abattis and Vergence Naturals Launch New Marketing Campaign

    VANCOUVER, British Columbia, May 24, 2018-- Abattis Bioceuticals Corp. and its wholly-owned subsidiary, Vergence Naturals Ltd., have launched their“ Live. ”marketing campaign to build awareness for their ...

  • GlobeNewswire3 months ago

    Abattis Bioceuticals Announces Release of New Line of Vaporizers

    Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce the addition of three new vaporizers to its product line. Since the Company’s acquisition of Green Tree Therapeutics (“Green Tree”) earlier this year, Abattis has been working to expand its retail presence and product line and is now ready to release its first three vaporizers, the VB-1, VB-2 and the KB-1.

  • ACCESSWIRE4 months ago

    Abattis Bioceuticals is Combining Cannabis Products and Blockchain Tech

    NEW YORK, NY / ACCESSWIRE / May 1, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Abattis Bioceuticals Corp. (ATTBF), a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. In March 2018 Abattis announced it has officially rebranded itself as a one-stop provider of downstream cannabis solutions for licensed producers and manufacturers of cannabinoid-containing products. The Company's new focus on downstream solutions reflects several of its recent acquisitions and the success of its fully integrated services offerings.

  • Newsfile4 months ago

    Abattis Completes Acquisition of Remaining Minority Interest in Gabriola Green Farms

    Vancouver, British Columbia--(Newsfile Corp. - April 30, 2018) - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT / OTC: ATTBF) is pleased to announce, further to its news release dated April 18, 2018, that it has completed its acquisition of the remaining 10% ownership interest (the "Interest") in its subsidiary, Gabriola Green Farms Inc. ("Gabriola"). Abattis acquired the Interest from CannaNUMUS Blockchain Inc. for $2.5 million. Gabriola is now a wholly-owned subsidiary of the ...

  • Newsfile4 months ago

    Abattis Enters into Agreement to Acquire Remaining Minority Interest in Gabriola Green Farms

    Vancouver, British Columbia--(Newsfile Corp. - April 18, 2018) - Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) (the "Company" or "Abattis") is pleased to announce that it has entered into a share purchase agreement to acquire (the "Acquisition") the remaining 10% ownership interest in its subsidiary, Gabriola Green Farms Inc. ("Gabriola")."We are very happy to now own a 100% interest in Gabriola and integrate it as a wholly-owned subsidiary of Abattis. We believe that Gabriola's anticipated LP ...

  • Newsfile4 months ago

    Abattis Announces Board Changes

    Vancouver, British Columbia--(Newsfile Corp. - April 13, 2018) - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT) (OTCQB: ATTBF) is pleased to announce the addition of Cameron Paddock to the Board of Directors. Mr. Paddock will fill the vacancy left by the resignation of Dr. Will Panenka who is leaving the Company to concentrate on other ventures."We are very excited have Mr. Paddock join our Board. On behalf of the Company, I would like ...

  • Newsfile5 months ago

    Abattis Provides Correction to March 13, 2018 News Release

    Vancouver, British Columbia--(Newsfile Corp. - March 26, 2018) - Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) (the "Company" or "Abattis") announces a correction to its news release dated March 13, 2018 (the "Release"). In the Release, Canadian Artesian Ice Ltd. ("Canadian Artesian") was described as being the bottlers of Clearly Canadian products. However, the Company has since been advised that Canadian Artesian are not the bottlers of Clearly Canadian products. About Abattis Bioceuticals Corp. Abattis ...

  • PR Newswire5 months ago

    Abattis Signs LOI with Canadian Artesian Ice, Bottlers of Clearly Canadian Products, to Manufacture CBD-infused Mineral Water

    Abattis Bioceuticals Corp. (the "Company" or "Abattis ") (CSE:ATT) (ATTBF) is pleased to announce it has entered into a non-binding letter of intent (the "LOI") with Canadian Artesian Ice Ltd. ("Canadian Artesian") to provide Canadian Artesian with, among other things, THC- and pesticide-free cannabidiol ("CBD") isolate, research and development services, nanoencapsulation and nanoemulsification services, analytical and regulatory services and access to Abattis's distribution and marketing channels to support the development, scalability and commercialization of a CBD-infused water for Canadian Artesian. Canadian Artesian is a bottler of Premium artesian 7.8 pH mineral water, based in Nelson, British Columbia, and is the bottler of Clearly Canadian Artesian mineral water.